Form D · Biotechnology

Silexion Therapeutics Corp

Ramat Gan, L3 · CIK 0002022416

Offering snapshot reported Aug 11, 2025 · SEC filing

Reported sold
$3.6M
Offering amount: $3.6M
Investors reported
11
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 1, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 11, 2025Initial$3,597,662No comparison11SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$141K
Finders' fees
$910K
Form D file number
021-554233
Form D covers new warrants issued 8/1/2025: investor warrants (304,212 at $11.32/share) and agent warrants (10,647 at $14.4625/share). Excludes exercise of warrants issued Jan 2025. Total offering amount equals exercise price of new warrants.
7% cash fee + 1% mgmt. fee to H.C. Wainwright on warrant exercise proceeds. Finder's fees: $25,000 expense allowance, $50,000 legal/out-of-pocket expenses, & $15,950 clearing fees. HCW agent warrants instead included in Item 13.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
H.C. Wainwright & Co., LLC000000375

Source: Form D, filed Aug 11, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Dror Abramov Director
Ruth Alon Director
Ilan Hadar Director, Executive
Mirit Horenshtein Hadar Executive
Ilan Levin Director
Avner Lushi Director
Shlomo Noy Director
Amnon Peled Director
Mitchell Shirvan Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
12 Abba Hillel Road
Ramat Gan, L3, 5250606